Myriad Genetics' Management Presents At 22nd Annual Oppenheimer Healthcare Conference - Conference Call Transcript

Myriad Genetics, Inc. (MYGN)

22nd Annual Oppenheimer Healthcare Conference Call

December 14, 2011 9:40 a.m. ET

Executives

Mark Capone - President

Rebecca Chambers - Director, Investor Relations and Corporate Communications

Analysts

David Ferreiro - Oppenheimer & Co.

Presentation

David Ferreiro - Oppenheimer & Co.

Compare to:
Previous Statements by MYGN
» Myriad Genetics' CEO Discusses F1Q12 Results - Earnings Call Transcript
» Myriad Genetics' CEO Discusses Q4 2011 Results - Earnings Call Transcript
» Myriad Genetics Inc. F2Q10 Earnings Conference Call

David Ferreiro with life science tools and diagnostics analyst. Welcome to second day of the Oppenheimer Healthcare Conference. Very happy to have Myriad Genetics here today, one of the premier molecular diagnostics companies out there in the U.S. right now. From Myriad today are Mark Capone, President of Myriad Genetics Laboratory, and also Rebecca Chambers to make sure that nothing inappropriate is said. So with that I will turn it over to Mark.

Mark Capone

Thank you, David, and good morning to everybody. We are going to thank Oppenheimer for the opportunity to be at the conference today and hopefully this presentation will be a beginning to a joyous holiday season for all of you. I am privileged today to talk about Myriad and where we are going as a company and our opportunities for growth. As always I may make forward-looking statements and we would encourage you to look to our website for our detailed SEC filings, where we’ll outline the risks that are associated with any investment in Myriad Genetics.

Myriad is industry leader in what we like to call transformative molecular diagnostic products. These are products that we think can fundamentally change the way that healthcare is delivered in this country and around the world. Myriad has broad scale capabilities. We have got nine innovative products that are on the market now, 13 in the pipeline. A 350 person sales force and a 182 issued patents.

1 2 3 Next › Last »